Regeneron released a strong financial report for Q3 and was the 15th of 16 in the last four years. Read why I upgrade REGN ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report third-quarter results on Oct. 31, 2024. The Zacks ...

Third quarter 2024 revenues increased 11% to $3.72 billion versus third quarter 2023Third quarter 2024 Dupixent® global net sales(recorded by ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) will present data from the Phase 3 LIBERTY-CUPID Study C evaluating the investigational use ...

Within the Sanofi antibody collaboration, LDL cholesterol reduction drug Praluent has seen a slow launch trajectory because of payer restrictions, but we think US sales growth can rebound now that ...

Patients in this study saw improvements in difficult-to-treat areas when treated with Ebglyss. With Ebglyss, 57% of patients in Week 16 and 60% in Week 24 who had previously been treated with ...

On Friday, Sanofi SA (NASDAQ:SNY) reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), ...

Sanofi said its Opella business has been valued at around 16 billion euros (USD17.38 billion), or 14 times EBITDA in 2024 ...

SALES FORECAST: The Paris-based group's sales are forecast at 12.63 billion euros, according to Visible Alpha. That compares with 11.96 billion euros for the same period the year before. As of ...

Sanofi to present dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria at ACAAI: Paris Saturday, October 26, 2024, 12:00 Hrs [IST] Positive data from the ...

More than 1,000,000 patients are being treated with Dupixent globally. Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has been ...

Hence, investors should also focus on Dupixent’s performance, sales of which are recorded by Sanofi SNY. Regeneron has a collaboration agreement with Sanofi for drugs like Dupixent and Kevzara.